FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Halmosi

Research Profile

Living Beings

Chemicals & Drugs

Physiology

Phenomena

Phosphorylation

Disorders

Co-author Network

Publications

TOP 3
K Magyar; Anita Palfi; Balazs Sumegi; I Battyany; Laszlo Czopf; Gergely Feher; A Fulop; Robert Halmosi; Kalman Toth; Eszter Szabados
Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease.
Eva Bartha; Domokos Gero; Kálmán Hideg; Tamas Kalai; Klara Magyar; Gabor Olah; Izabella Solti; Balazs Sumegi; Eszter Szabados; Aliz Szabo; Csaba Szabó; Kalman Toth; Robert Halmosi
Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.
István Kiss; Antal Tibold; Robert Halmosi; Eva Bartha; Katalin Koltai; Zsuzsanna Orsós; László Bujdosó; István Ember
Enhancement of organ regeneration in animal models by a stem cell-stimulating plant mixture.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Halmosi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: K Magyar; Anita Palfi; Balazs Sumegi; I Battyany; Laszlo Czopf; Gergely Feher; A Fulop; Robert Halmosi; Kalman Toth; Eszter Szabados
Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease.
Clinical hemorheology and microcirculation 2012;50(3):179-87.
2011: Eva Bartha; Domokos Gero; Kálmán Hideg; Tamas Kalai; Klara Magyar; Gabor Olah; Izabella Solti; Balazs Sumegi; Eszter Szabados; Aliz Szabo; Csaba Szabó; Kalman Toth; Robert Halmosi
Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.
Journal of cardiovascular pharmacology 2011;58(4):380-91.
2010: István Kiss; Antal Tibold; Robert Halmosi; Eva Bartha; Katalin Koltai; Zsuzsanna Orsós; László Bujdosó; István Ember
Enhancement of organ regeneration in animal models by a stem cell-stimulating plant mixture.
Journal of medicinal food 2010;13(3):599-604.
2009: Eva Bartha; Izabella Solti; Laszlo Kereskai; Janos Lantos; Eniko Plozer; Klara Magyar; Eszter Szabados; Tamás Kálai; Kálmán Hideg; Robert Halmosi; Balazs Sumegi; Kalman Toth
PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
Cardiovascular research 2009;83(3):501-10.
2008: Eva Bartha; Gyongyi N Kiss; Endre Kalman; Gyozo Kulcsár; Tamás Kálai; Kálmán Hideg; Tamas Habon; Balazs Sumegi; Kalman Toth; Robert Halmosi
Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
Journal of cardiovascular pharmacology 2008;52(3):253-61.
2006: Anita Palfi; Ambrus Toth; Katalin Hanto; Peter Deres; Eszter Szabados; Zoltan Szereday; Gyozo Kulcsar; Tamas Kalai; Kálmán Hideg; Ferenc Gallyas Jr; Balazs Sumegi; Kalman Toth; Robert Halmosi
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Journal of molecular and cellular cardiology 2006;41(1):149-59.
2005: Anita Pálfi; Ambrus Tóth; Gyozo Kulcsár; Katalin Hantó; Peter Deres; Eva Bartha; Robert Halmosi; Eszter Szabados; Laszlo Czopf; Tamás Kálai; Kálmán Hideg; Balázs Sümegi; Kálmán Tóth
The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts.
The Journal of pharmacology and experimental therapeutics 2005;315(1):273-82.
2005: Elod Papp; Laszlo Czopf; Tamas Habon; Robert Halmosi; Beata Horvath; Zsolt Marton; Tamás Tahin; Andras Komocsi; Ivan Horvath; Béla Melegh; Kalman Toth
Drug-induced myocardial infarction in young patients: report of two cases.
International journal of cardiology 2005;98(1):169-70.
2005: Peter Deres; Robert Halmosi; Ambrus Toth; Krisztina Kovacs; Anita Palfi; Tamas Habon; Laszlo Czopf; Tamas Kalai; Kálmán Hideg; Balazs Sumegi; Kalman Toth
Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound.
Journal of cardiovascular pharmacology 2005;45(1):36-43.
2004: Zsolt Marton; Robert Halmosi; Tamas Alexy; Beata Horvath; Ambrus Toth; Gergely Feher; Katalin Koltai; Gabor Kesmarky; Tamas Habon; Balazs Sumegi; Kálmán Hideg; Kalman Toth
Hemorheological methods in drug research.
Clinical hemorheology and microcirculation 2004;30(3-4):243-52.
2003: Ambrus Toth; Krisztina Kovacs; Peter Deres; Robert Halmosi; Laszlo Czopf; Katalin Hanto; Tamas Kalai; Kálmán Hideg; Balazs Sumegi; Kalman Toth
Impact of a novel cardioprotective agent on the ischaemia-reperfusion-induced Akt kinase activation.
Biochemical pharmacology 2003;66(11):2263-72.
2003: Ambrus Toth; Robert Halmosi; Krisztina Kovacs; Peter Deres; Tamas Kalai; Kálmán Hideg; Kalman Toth; Balazs Sumegi
Akt activation induced by an antioxidant compound during ischemia-reperfusion.
Free radical biology & medicine 2003;35(9):1051-63.
2002: Robert Halmosi; Peter Deres; Ambrus Toth; Zoltan Berente; Tamas Kalai; Balazs Sumegi; Kálmán Hideg; Kalman Toth
2,2,5,5-Tetramethylpyrroline-based compounds in prevention of oxyradical-induced myocardial damage.
Journal of cardiovascular pharmacology 2002;40(6):854-67.
2002: Beáta Horváth; Zsolt Márton; Robert Halmosi; Tamas Alexy; László Szapáry; Judit Vékási; Zsolt Bíró; Tamas Habon; Gábor Késmárky; Kálmán Tóth
[Scavenger effect of various cerebrovascular drugs].
Orvosi hetilap 2002;143(1):13-7.
2002: Beata Horvath; Zsolt Marton; Robert Halmosi; Tamas Alexy; Laszlo Szapary; Judit Vekasi; Zsolt Biro; Tamas Habon; Gabor Kesmarky; Kalman Toth
In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine.
Clinical neuropharmacology 2002;25(1):37-42.
2001: Zsolt Marton; Robert Halmosi; Beata Horvath; Tamas Alexy; Gabor Kesmarky; Judit Vekasi; I Battyany; Kálmán Hideg; Kalman Toth
Scavenger effect of experimental and clinically used cardiovascular drugs.
Journal of cardiovascular pharmacology 2001;38(5):745-53.
2001: Tamas Habon; Eszter Szabados; Gábor Késmárky; Robert Halmosi; Tibor Past; Balazs Sumegi; Kálmán Tóth
[The effect of carvedilol on enhanced adp-ribosylation and red blood cell membrane damage caused by free radicals].
Acta pharmaceutica Hungarica 2001;71(3):306-13.
2001: Ambrus Toth; Zsolt Marton; Laszlo Czopf; Gabor Kesmarky; Robert Halmosi; István Juricskay; Tamas Habon; Kalman Toth
QRS Score: a composite index of exercise-induced changes in the Q, R, and S waves during exercise stress testing in patients with ischemic heart disease.
Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2001;6(4):310-8.
2001: Tamas Habon; Eszter Szabados; Gabor Kesmarky; Robert Halmosi; Tibor Past; Balazs Sumegi; Kalman Toth
The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals.
Cardiovascular research 2001;52(1):153-60.
2001: Robert Halmosi; Zoltan Berente; Erzsébet Osz; Kalman Toth; Peter Literati-Nagy; Balazs Sumegi
Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.
Molecular pharmacology 2001;59(6):1497-505.
2001: Gábor Késmárky; Kálmán Tóth; G Vajda; L Habon; Robert Halmosi; Erzsébet Róth
Hemorheological and oxygen free radical associated alterations during and after percutaneous transluminal coronary angioplasty.
Clinical hemorheology and microcirculation 2001;24(1):33-41.
1999: Kalman Toth; Gabor Kesmarky; Judit Vekasi; J Nemes; Laszlo Czopf; P Kapronczay; Robert Halmosi; Elod Papp; István Juricskay
Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment.
Clinical hemorheology and microcirculation 1999;21(3-4):209-16.